PMID- 17116940
OWN - NLM
STAT- MEDLINE
DCOM- 20070108
LR  - 20061220
IS  - 1527-7755 (Electronic)
IS  - 0732-183X (Linking)
VI  - 24
IP  - 36
DP  - 2006 Dec 20
TI  - Allogeneic marrow stem-cell transplantation from human leukocyte 
      antigen-identical siblings versus human leukocyte antigen-allelic-matched 
      unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a 
      prospective study from the French Society of Bone Marrow Transplantation and Cell 
      Therapy.
PG  - 5695-702
AB  - PURPOSE: To investigate the influence of donor type (human leukocyte antigen 
      [HLA] -identical sibling donor versus HLA-A-, HLA-B-, HLA-Cw-, HLA-DRB1-, and 
      HLA-DQB1-identical unrelated donors, or so-called 10/10) on the outcome of 
      patients who underwent allogeneic stem-cell transplantation (alloSCT), adjusting 
      for other prognostic factors, in patients with standard-risk hematologic 
      malignancy. PATIENTS AND METHODS: Between March 2000 and January 2003, we 
      prospectively investigated the outcome of 236 consecutive patients with 
      standard-risk malignancy from 12 French centers. Fifty-five patients underwent 
      alloSCT from an unrelated HLA-identical donor at the allelic level, whereas 181 
      patients received an alloSCT from an HLA-identical sibling. Diagnoses included 
      acute leukemia (n = 175), chronic myeloid leukemia (n = 43), and myelodysplastic 
      syndrome (MDS; n = 18). All patients received unmodified marrow graft following 
      myeloablative conditioning with cyclophosphamide and total-body irradiation. 
      Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine and 
      short-course methotrexate in all patients. RESULTS: In multivariable analysis, 
      overall survival and transplantation-related mortality were adversely influenced 
      by recipient cytomegalovirus (CMV) -positive serology, age of donor older than 37 
      years, and the occurrence of acute grade > or = II GVHD. Event-free survival 
      rates were lower for patients with recipient CMV-positive serology. Acute grades 
      II to IV GVHD rates were higher for patients with chronic myeloid leukemia (CML). 
      No factor was found to influence either relapse or acute grades III to IV GVHD. 
      The effect of donor type was nonsignificant for all criteria. CONCLUSION: In 
      patients with standard-risk malignancy, transplantation from unrelated 
      HLA-allellically matched donors led to outcomes similar to those from 
      HLA-identical sibling donors.
FAU - Yakoub-Agha, Ibrahim
AU  - Yakoub-Agha I
AD  - Agence de la biomedecine, St Denis, France.
FAU - Mesnil, Florence
AU  - Mesnil F
FAU - Kuentz, Mathieu
AU  - Kuentz M
FAU - Boiron, Jean Michel
AU  - Boiron JM
FAU - Ifrah, Norbert
AU  - Ifrah N
FAU - Milpied, Noel
AU  - Milpied N
FAU - Chehata, Sami
AU  - Chehata S
FAU - Esperou, Helene
AU  - Esperou H
FAU - Vernant, Jean-Paul
AU  - Vernant JP
FAU - Michallet, Mauricette
AU  - Michallet M
FAU - Buzyn, Agnes
AU  - Buzyn A
FAU - Gratecos, Nicole
AU  - Gratecos N
FAU - Cahn, Jean Yves
AU  - Cahn JY
FAU - Bourhis, Jean Henri
AU  - Bourhis JH
FAU - Chir, Zina
AU  - Chir Z
FAU - Raffoux, Colette
AU  - Raffoux C
FAU - Socie, Gerard
AU  - Socie G
FAU - Golmard, Jean Louis
AU  - Golmard JL
FAU - Jouet, Jean-Pierre
AU  - Jouet JP
CN  - French Society of Bone Marrow Transplantation and Cell Therapy
LA  - eng
PT  - Journal Article
DEP - 20061120
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
SB  - IM
MH  - Adult
MH  - Female
MH  - Hematologic Neoplasms/*therapy
MH  - *Histocompatibility Testing
MH  - Humans
MH  - Male
MH  - Prospective Studies
MH  - Siblings
MH  - *Stem Cell Transplantation
MH  - Survival Analysis
MH  - Transplantation, Homologous
MH  - Treatment Outcome
EDAT- 2006/11/23 09:00
MHDA- 2007/01/09 09:00
CRDT- 2006/11/23 09:00
PHST- 2006/11/23 09:00 [pubmed]
PHST- 2007/01/09 09:00 [medline]
PHST- 2006/11/23 09:00 [entrez]
AID - JCO.2006.08.0952 [pii]
AID - 10.1200/JCO.2006.08.0952 [doi]
PST - ppublish
SO  - J Clin Oncol. 2006 Dec 20;24(36):5695-702. doi: 10.1200/JCO.2006.08.0952. Epub 
      2006 Nov 20.